Attention anti-vaccinators: Skin reactions to mRNA COVID-19 vaccines are no cause for alarm

An extensive review of the literature finds the most frequently reported reactions have been misrepresented or exaggerated in the media and are rarely cause for concern, University of Connecticut researchers report in Clinics in Dermatology

Philadelphia, June 22, 2021

Vivid photos of the red 'COVID arm' rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy. A comprehensive review in Clinics in Dermatology, conducted by University of Connecticut School of Medicine researchers and published by Elsevier, confirms that almost all cutaneous reactions are largely self-limited and should not discourage getting the vaccine.

The authors reviewed literature published as of May 2021 describing cutaneous side effects from the currently authorized m-RNA vaccines and supplemented their analysis with data from the Centers for Disease Control and Prevention's Vaccine Adverse Event Reporting System (CDC-VAERS).

'Usually, the cutaneous reactions described are not a cause for concern,' explained co-author Christian Gronbeck, MD, UConn School of Medicine, Farmington, CT, USA. 'Existing reports should reassure patients of the overall compelling safety profiles and benignity of skin reactions following mRNA COVID-19 vaccination.'

Local injection site reactions may occur shortly after vaccine administration and may take the form of swelling, redness/erythema and/or pain. The incidence rate reported in studies reviewed by Dr. Gronbeck and his coauthor Jane M. Grant-Kels, MD, UConn School of Medicine Department of Dermatology, Farmington, CT, USA, range from 5.5 percent to 23.7 percent. The published reports agree that these reactions are harmless, transient, and largely resolve within two to five days. It is important to distinguish these reactions from immediate allergic-type hypersensitivity reactions, such as angioedema, respiratory distress, or anaphylaxis that occur within four hours of vaccination. However, existing studies provide reassurance to patients and providers because dermatological symptoms are transient and rarely associated with anaphylaxis.

Delayed local reactions, typically erythema with mild hardening of the tissue at the injection site, occur days rather than hours, after injection with the Moderna vaccine. They are temporary and may be less frequent after the second dose. They likely represent T-cell-mediated hypersensitivity, and the authors agree that they likely do not lessen vaccine safety. 'Recognition of delayed reactions is nonetheless important,' Dr. Gronbeck and Dr. Grant-Kels said, 'to both guide patient expectations and avoid unnecessary medical treatment.'

A new study concludes that while further studies are needed to understand the reaction mechanisms and management approaches for cutaneous vaccination reactions, the research published to date should provide reassurance to all regarding the safety of these vaccines vis-à-vis the skin (Credit: iStock.com/SyhinStas).

Rarely reported and more unusual cutaneous reactions to the mRNA COVID-19 vaccines have occurred, although reports are very limited and it is difficult to identify overall incidence rates. Crusted, vesicular, painful skin lesions, consistent with herpes zoster reactivation, have been reported following both the Pfizer and Moderna vaccines. It has been postulated that immunomodulary effects of the COVID-19 vaccines may have promoted zoster reactivation and further studies are needed. In the meantime, the authors suggest heightened monitoring for patients with risk factors.

Several cases of facial swelling in patients with a history of dermatological fillers have been reported after COVID-19 vaccination. Although rare, these events are important to recognize amidst the expansion of vaccines to the general population and the growing popularity of dermal fillers.

The CDC-VAERS currently lists 260 reports of immune thrombocytopenia (ITP), a disorder characterized by excessive bruising and bleeding caused by lowered platelet levels. Case reports suggest that it may present differently and occur in varying patient populations. Some studies hypothesize that the cause may be immune-mediated platelet destruction following the COVID vaccine. However, given the overall rarity, researchers have also considered that underlying autoimmune or another disease may play a role. Optimal treatment must be further studied, given that aggressive immunosuppression may dampen the desired immune response from the vaccines.

The authors observed that most studies and the VAERS data do not include incidence rates among all vaccinated individuals, making it difficult to estimate the specific frequency of each reaction. Also, many studies reported reactions in healthcare workers, which may not reflect the broader population. Despite these shortcomings, Dr. Grant-Kels said, 'We propose several reassuring clinical considerations for those who are hesitant to be vaccinated. First, the reported reactions are largely self-limited, and the most frequent reactions were also found in the clinical trials of the drugs, which have been authorized for use in the general population. Allergic-type symptoms are transient and rarely associated with anaphylaxis. The development of uncommon reactions such as herpes zoster, dermal filler reactions, and ITP were seldom serious in nature but justify clinical monitoring.'

The authors noted that while further studies are needed to understand the reaction mechanisms and management approaches for cutaneous vaccination reactions, the research published to date should provide reassurance to all regarding the safety of these vaccines vis-à-vis the skin.

---

Notes for editors
The article is 'Attention all Anti-Vaccinators: The Cutaneous Adverse Cutaneous Events from the mRNA COVID-19 Vaccines Are Not an Excuse to Avoid Them!'by Christian Gronbeck and Jane M. Grant-Kels (https://doi.org/10.1016/j.clindermatol.2021.05.027). It appears online in Clinics in Dermatology published by Elsevier.

The article is openly available at https://www.sciencedirect.com/science/article/pii/S0738081X21001085.

Full text of this study is also available to credentialed journalists upon request; contact Bobby Brinson at [e-mail]. Journalists wishing to interview the authors should contact Carolyn Pennington, UConn Health Communications, at [phone]; [e-mail], or UConn Health, Division of Dermatopathology at [phone].

Elsevier's Novel Coronavirus Information Center provides expert-curated information for researchers, healthcare professionals and public health officials, including clinical guidance and a portal to access all of Elsevier's COVID-19 research. All resources are freely available. We also have dedicated hubs for healthcare professionals; health educators and students; librarians; and R&D professionals. You can find these in our Coronavirus Resource Directory.

About Clinics in Dermatology
Clinics in Dermatology, the official journal of the International Academy of Cosmetic Dermatology (IACD), publishes the most practical and comprehensive information on the treatment and care of skin disorders. Each issue features a Guest Editor and is devoted to a single timely topic relating to clinical dermatology. www.cidjournal.com

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.